🇪🇺 Revasc in European Union

EMA authorised Revasc on 9 July 1997

Marketing authorisation

EMA — authorised 9 July 1997

  • Application: EMEA/H/C/000104
  • Marketing authorisation holder: Canyon Pharmaceuticals Ltd.
  • Local brand name: Revasc
  • Indication: Prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.
  • Status: withdrawn

Read official source →

Revasc in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Cardiovascular approved in European Union

Frequently asked questions

Is Revasc approved in European Union?

Yes. EMA authorised it on 9 July 1997.

Who is the marketing authorisation holder for Revasc in European Union?

Canyon Pharmaceuticals Ltd. holds the EU marketing authorisation.